Prohibitin-targeting peptide 1

Prohibitin-targeting peptide 1Clinical data

Trade names| Adipotide
Other names| Prohibitin-TP01; TP01
Legal status
Legal status|

* Investigational

Identifiers
CAS Number|

* 859216-15-2

Prohibitin-targeting peptide 1 (also known as prohibitin-TP01 and TP01; trade name Adipotide) is a peptidomimetic with sequence CKGGRAKDC-GG-D(KLAKLAK)2. It is an experimental proapoptotic drug[1] that has been shown to cause rapid weight loss in mice[2] and rhesus monkeys.[3] Its mechanism of action is to target specific blood vessels supplying adipose tissue with blood, cause the vessels to shrink and the fat cells fed by those vessels to undergo apoptosis.[4] TP01 is designed to bind to two receptors, ANXA2 and prohibitin, that are specific to blood vessels supplying white adipose tissue.[5]

As of 2019, clinical development has been discontinued.[6]

## References

[edit]

1. ^ "Prohibitin-targeting peptide 1". NCI Drug Dictionary. National Cancer Institutes. 2 February 2011.
2. ^ Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W (June 2004). "Reversal of obesity by targeted ablation of adipose tissue". Nature Medicine. 10 (6). Nature Publishing Group: 625–32. doi:10.1038/nm1048. PMID 15133506. S2CID 19369938.
3. ^ "Blood vessel mapping reveals four new 'ZIP codes'". medicalxpress. 24 October 2011. Retrieved 10 November 2011.
4. ^ Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, et al. (November 2011). "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys". Science Translational Medicine. 3 (108): 108ra112. doi:10.1126/scitranslmed.3002621. PMC 3666164. PMID 22072637.
5. ^ Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, et al. (November 2011). "Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients". Proceedings of the National Academy of Sciences of the United States of America. 108 (46): 18637–42. Bibcode:2011PNAS..10818637S. doi:10.1073/pnas.1114503108. PMC 3219136. PMID 22049339.
6. ^ "Prohibitin targeting peptide 1". Adis Insight. Springer Nature Switzerland AG.

* v
* t
* e

Targeted cancer therapy / antineoplastic agents (L01)

CI monoclonal antibodies ("-mab")|

| Receptor tyrosine kinase|

* ErbB: HER1/EGFR (Cetuximab
* Panitumumab)
* HER2/neu (Pertuzumab, Trastuzumab (+hyaluronidase)
* Trastuzumab emtansine
* Trastuzumab deruxtecan)

|

Others for solid tumors|

* EpCAM (Catumaxomab
* Edrecolomab)
* VEGF-A (Bevacizumab)

Leukemia/lymphoma|

* lymphoid: CD3 (Glofitamab, Elranatamab, Mosunetuzumab), CD20 (Glofitamab
* Ibritumomab
* Mosunetuzumab
* Obinutuzumab
* Ofatumumab
* Rituximab
* Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab)

* myeloid: CD33 (Gemtuzumab ozogamicin)

Other|

* Amivantamab
* Atezolizumab
* Avelumab
* Axatilimab
* Belantamab mafodotin
* Bermekimab
* Blinatumomab
* Cemiplimab
* Daratumumab
* Dinutuximab beta
* Dostarlimab
* Durvalumab
* Elotuzumab
* Enfortumab vedotin
* Epcoritamab
* Inotuzumab ozogamicin
* Ipilimumab
* Isatuximab
* Loncastuximab tesirine
* Mirvetuximab soravtansine
* Mogamulizumab
* Moxetumomab pasudotox
* Naxitamab
* Necitumumab
* Nivolumab
* Olaratumab
* Oportuzumab monatox
* Pembrolizumab
* Polatuzumab vedotin
* Prolgolimab
* Ramucirumab
* Retifanlimab
* Sabatolimab
* Sacituzumab govitecan
* Serplulimab
* Sugemalimab
* Tafasitamab
* Talquetamab
* Tarlatamab
* Teclistamab
* Tislelizumab
* Tisotumab vedotin
* Toripalimab
* Tremelimumab

Tyrosine kinase inhibitors ("-nib")|

| Receptor tyrosine kinase|

* ErbB: HER1/EGFR (Afatinib
* Aumolertinib
* Brigatinib
* Dacomitinib
* Erlotinib
* Gefitinib
* Icotinib
* Lazertinib
* Mobocertinib
* Olmutinib
* Osimertinib
* Rociletinib
* Vandetanib)

* HER1/EGFR and HER2/neu
* Lapatinib
* Neratinib
* Tucatinib

* RTK class III: C-kit and PDGFR (Avapritinib
* Axitinib
* Masitinib
* Pazopanib
* Ripretinib
* Sorafenib
* Sunitinib
* Toceranib)
* FLT3 (Lestaurtinib, Gilteritinib (AXL, ALK, LTK))

* VEGFR
* Axitinib
* Cediranib
* Fruquintinib
* Lenvatinib
* Nintedanib
* Pazopanib
* Regorafenib
* Semaxanib
* Sorafenib
* Sunitinib
* Tivozanib
* Toceranib
* Vandetanib

* ALK
* Alectinib
* Brigatinib
* Ceritinib

* RET inhibitors: Entrectinib (ALK, ROS1, NTRK), Futibatinib (FGFR2), Infigratinib, Larotrectinib (NTRK), Pemigatinib (FGFR), Pralsetinib, Repotrectinib (ROS1, TRK, ALK), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).

* c-MET inhibitors: Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)

|

Non-receptor|

* bcr-abl
* Asciminib
* Bosutinib
* Dasatinib
* Imatinib
* Nilotinib
* Ponatinib
* Radotinib

* Src (Bosutinib
* Dasatinib)

* Janus kinase
* Baricitinib
* Fedratinib
* Filgotinib
* Lestaurtinib
* Momelotinib
* Pacritinib
* Ruxolitinib

* MAP2K
* Binimetinib
* Cobimetinib
* Selumetinib
* Trametinib

* EML4-ALK
* Crizotinib
* Entrectinib
* Lorlatinib

* Bruton's
* Acalabrutinib
* Ibrutinib
* Orelabrutinib
* Pirtobrutinib
* Zanubrutinib

Other|

* fusion protein against VEGF (Aflibercept)
* proapoptotic peptide against ANXA2 and prohibitin (Adipotide)
* exotoxin against IL-2 (Denileukin diftitox)
* mTOR inhibitors
* Everolimus
* Ridaforolimus
* Temsirolimus
* hedgehog inhibitors
* Glasdegib
* Sonidegib
* Vismodegib
* CDK inhibitors
* Abemaciclib
* Dalpiciclib
* Palbociclib
* Ribociclib
* Trilaciclib
* KRAS inhibitors
* Adagrasib
* Sotorasib
* Pi3K inhibitors
* Alpelisib
* Copanlisib
* Duvelisib
* Idelalisib
* Parsaclisib
* Cabozantinib
* Capmatinib
* Entrectinib
* Erdafitinib
* Gilteritinib
* Larotrectinib
* Lenvatinib
* Masitinib
* Midostaurin
* Nintedanib
* Odronextamab
* Pazopanib
* Pemigatinib
* Pexidartinib
* Quizartinib
* Regorafenib
* Ripretinib
* Sorafenib
* Sunitinib
* Tebentafusp
* Tepotinib
* Vandetanib
* Venetoclax

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template